Skip to main content
Andrew Shorr, MD, Pulmonology, Washington, DC, MedStar Washington Hospital Center

AndrewFrazierShorrMD

Pulmonology • Washington, DC

Critical Care Medicine, Pleural Disease

Associate Professor, Medicine, Georgetown University School of Medicine

Join to view full profile

Dr. Shorr is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shorr's full profile

Already have an account?

Education & Training

  • National Capital Consortium
    National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1997 - 2000
  • National Capital Consortium
    National Capital ConsortiumResidency, Internal Medicine, 1994 - 1997
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 1995

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2000 - 2025
  • DC State Medical License
    DC State Medical License 2005 - 2024
  • VA State Medical License
    VA State Medical License 1996 - 2000
  • PA State Medical License
    PA State Medical License 1997 - 2000
  • American Board of Internal Medicine Critical Care Medicine
  • American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (Sulbactam for Injection; Durlobactam for Injection), Co-Packaged for Intravenous Use
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (Sulbactam for Injection; Durlobactam for Injection), Co-Packaged for Intravenous UseMay 23rd, 2023
  • FAQs: Improving Empiric Antibiotic Regimens for HABP/VABP in the ICU
    FAQs: Improving Empiric Antibiotic Regimens for HABP/VABP in the ICUDecember 6th, 2022
  • Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
    Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe PneumoniaAugust 25th, 2021
  • Join now to see all

Hospital Affiliations

Dr. Andrew Shorr, Dr. Andrew Shorr, MD, Dr. A Shorr, Dr. Andrew Frazier Shorr